News from the PREFER project
- Watch PREFER on YouTube 2018-02-21
- Follow PREFER on twitter! 2018-02-16
- PREFER Annual meeting 2018 2017-12-13
- Preference research from the patient perspective 2017-11-22
- PREFER at ISPOR 2017 2017-11-07
- Data management in PREFER 2017-07-05
- PREFER annual meeting 2017 2017-07-05
- Patient preferences in healthcare decision-making 2017-05-16
- PREFER PhD project on rheumatoid arthritis 2017-04-06
- Editorial in Patient: Giving patients’ preferences a voice in medical treatment life cycle 2017-03-16
- New research initiative on patient preferences 2016-11-16
- ETHICS BLOG: How to listen to (the right) patient voices? 2016-10-25
- Giving patients a voice in drug development 2016-10-18
- Value in Health publishes theme section on patient preferences 2016-10-05
- PREFER kick-off 27-28 October 2016-09-30
- HTA and Payers Stakeholder Advisory Group formed 2016-09-02
- Patient advisory group formed 2016-09-01
- The science of patient input 2016-08-31
- Age, education and health literacy affects how people understand risk 2012-09-01
We are developing evidence-based recommendations to guide industry, regulatory authorities, HTA bodies, reimbursement agencies, and health care professionals. We start with work to assess methodologies. After that, we test them in clinical case studies. This work will be the basis for the recommendations we make.
Together with stakeholders
PREFER is a public-private partnership with collaboration at every level, making sure we get more than one perspective on everything we do. We have stakeholder partners from Health Technology Assessment bodies and patient organisations. We are also working closely with regulators to ensure recommendations are evidence based, relevant and useful.
Challenges and opportunities in patient preference assessment
Patient preferences are taking on an increasingly important role in the lifecycle of medical products. The methods to assess preferences are many, and PREFER will contribute knowledge on which methods are best suited at different points. As part of his PhD project, Vikas Soekhai will help identify methods and simulate the impact the choice of method may have on preference study results.
Vikas Soekhai's PhD will contribute to PREFER knowledge on the challenges and opportunities involved in assessments of patient preferences throughout the whole lifecycle of drugs and medical devices.
The patient voice in preference research
Patient organisations provide a strong and united patients’ voice, placing patients at the centre of EU Health policy and the forefront of research programmes. Through various Innovative Medicines Initiative (IMI) projects, including PREFER, patient advocates voices have become increasingly present in all aspects of drug development: from fundamental research to regulatory aspects, pricing and reimbursement decisions at the EU-level.
Isabelle Manneh Vangramberen, Pharmacist, Public Health Professional, EU Expert and a patient advocate at the European Cancer Patient Coalition (ECPC), leads patient input through the PREFER patient stakeholder advisory group. Here, she shares the patient perspective and her view on how it is represented in PREFER.
Finding out what patients prefer
Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when and where patients want, can, and should be involved in drug development.
We are looking forward to sharing our findings with you!
Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader
Innovative Medicines Initiative
PREFER is funded by the Innovative Medicines Initiative (IMI): a part of the EU Horizon 2020 Programme.
The academic research in PREFER is funded by Horizon 2020: the EU Framework Programme for Research and Innovation.
The pharmaceutical industry contributes equally to the PREFER project. Industry input to the IMI programme is organised by EFPIA.